
    
      Using [99mTc]-labeled anti-PDL1 single-domain antibody, this study aims to prospectively
      measure changes in PD-L1 expression determined with SPECT imaging and correlate these changes
      with response to anti-PD(L)1 immunotherapy.
    
  